2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
58
Leukemia
52
Lymphoma
37
Myelodysplastic Syndromes
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Lymphoma, Non-Hodgkin
22
Hodgkin Disease
22
Leukemia, Myeloid, Acute
18
Multiple Myeloma
17
Myeloproliferative Disorders
14
Recurrence
12
Lymphoma, Mantle-Cell
12
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma, T-Cell, Peripheral
10
Lymphoma, Follicular
10
Congenital Abnormalities
10
Neoplasms, Plasma Cell
9
Lymphoma, B-Cell, Marginal Zone
9
Leukemia, Myeloid, Chronic-Phase
9
Hematologic Neoplasms
9
Burkitt Lymphoma
9
Anemia, Aplastic
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Waldenstrom Macroglobulinemia
7
Myelodysplastic-Myeloproliferative Diseases
7
Lymphoma, T-Cell
7
Lymphoma, Large-Cell, Immunoblastic
7
Graft vs Host Disease
7
Sezary Syndrome
6
Primary Myelofibrosis
6
Interventions
HhAntag691
25
Imiquimod
12
Biopsy
12
sonidegib
11
Aminolevulinic Acid
9
cemiplimab
8
Photochemotherapy
8
Nivolumab
8
methyl 5-aminolevulinate
7
Mohs Surgery
7
1-phenyl-3,3-dimethyltriazene
7
Tomography, Optical Coherence
6
Surgical Procedures, Operative
6
Specimen Handling
5
Radiotherapy
5
Itraconazole
5
pembrolizumab
4
daromun
4
Microscopy, Confocal
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Curettage
4
Standard of Care
3
Niacinamide
3
IPI-926
3
CTLA-4 Antigen
3
3-ingenyl angelate
3
tazarotene
2
talimogene laherparepvec
2
relatlimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Basal Cell
×
Alemtuzumab
×
Clear all
NCT06705608
2024-11-26
MS; FTY720
University of British Columbia
Completed
4,000 enrolled